Feasibility Study of Deep Learning-based MDixon Quant for Quantitative Assessment of Chemotherapy-induced Fatty Liver

Sponsor
Yunnan Cancer Hospital
Study ID
NCT06735118
Status
Recruiting
Apply to this trial

Conditions

  • Non-Alcoholic Fatty Liver Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • Neoadjuvant chemotherapy — DRUG
    Neoadjuvant chemotherapy

Study Details

The purpose of this study is to quantitatively assess the changes in liver fat content in cancer patients before and after treatment. The main questions it aims to answer are:How does the liver fat fraction change before and after chemotherapy? In this study, patients undergoing mDixon Quant scanning are subjected to fully automated segmentation and measurement of liver fat content using artificial intelligence.

Key Dates

First listed
Dec 16, 2024
Start date
Dec 25, 2023
Status verified
Dec 2024
Primary completion
Dec 30, 2024
Completion
Dec 30, 2024

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: neoadjuvant chemotherapy group
    Cancer patients undergoing chemotherapy.
  • No Intervention: Non-neoadjuvant chemotherapy group
    Cancer patients not undergoing chemotherapy.

Primary Outcome Measure

Extract the whole liver fat fraction [ Time Frame: one year ]

Central Contacts

Related Studies